KP Tissue Releases Second Quarter 2025 Financial Results
| Kruger Products Inc. | ||||||
| Unaudited Condensed Consolidated Statements of Financial Position | ||||||
| (thousands of Canadian dollars) | ||||||
| June 30, 2025 | December 31, 2024 | |||||
| $ | $ | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | 85,307 | 119,460 | ||||
| Restricted cash | 76,325 | 48,375 | ||||
| Trade and other receivables | 132,700 | 138,177 | ||||
| Receivables from related parties | 80 | 80 | ||||
| Inventories | 302,251 | 287,756 | ||||
| Income tax recoverable | 4,007 | 3,208 | ||||
| Prepaid expenses | 17,703 | 6,383 | ||||
| 618,373 | 603,439 | |||||
| Non-current assets | ||||||
| Property, plant and equipment | 1,449,424 | 1,509,592 | ||||
| Right-of-use assets | 167,865 | 186,460 | ||||
| Other long-term assets | 10 | 92 | ||||
| Pensions | 91,235 | 92,661 | ||||
| Goodwill | 152,021 | 152,021 | ||||
| Intangible assets | 40,592 | 42,572 | ||||
| Deferred income taxes | 10,249 | 10,500 | ||||
| Total assets | 2,529,769 | 2,597,337 | ||||
| Liabilities | ||||||
| Current liabilities | ||||||
| Trade and other payables | 311,583 | 346,264 | ||||
| Payables to related parties | 12,473 | 17,829 | ||||
| Income tax payable | - | 3 | ||||
| Dividends payable | 14,595 | 14,308 | ||||
| Current portion of long-term debt | 79,981 | 54,168 | ||||
| Current portion of lease liabilities | 41,003 | 40,156 | ||||
| Current portion of long-term payable to related party | 5,800 | 5,800 | ||||
| Current portion of provisions | 5,795 | 4,184 | ||||
| 471,230 | 482,712 | |||||
| Non-current liabilities | ||||||
| Long-term debt | 1,125,503 | 1,180,488 | ||||
| Long-term lease liabilities | 154,513 | 165,563 | ||||
| Long-term payable to related party | 27,147 | 31,925 | ||||
| Long-term provisions | 7,872 | 9,398 | ||||
| Pensions | 17,371 | 17,845 | ||||
| Post-retirement benefits | 47,989 | 47,140 | ||||
| Total liabilities | 1,851,625 | 1,935,071 | ||||
| Equity | ||||||
| Share capital | 321,455 | 308,622 | ||||
| Contributed surplus | 395,382 | 395,382 | ||||
| Deficit | (162,522 | ) | (171,874 | ) | ||
| Accumulated other comprehensive income | 88,346 | 100,177 | ||||
| Equity attributable to Kruger Products | 642,661 | 632,307 | ||||
| Non-controlling interest | 35,483 | 29,959 | ||||
| Total equity | 678,144 | 662,266 | ||||
| Total equity and liabilities | 2,529,769 | 2,597,337 |
| Kruger Products Inc. | |||||||||
| Unaudited Condensed Consolidated Statements of Income | |||||||||
| (thousands of Canadian dollars) | |||||||||
| 3-month period ended June 30, 2025 | 3-month period ended June 30, 2024 | 6-month period ended June 30, 2025 | 6-month period ended June 30, 2024 | ||||||
| $ | $ | $ | $ | ||||||
| Revenue | 536,080 | 509,800 | 1,082,190 | 989,232 | |||||
| Expenses | |||||||||
| Cost of sales | 462,204 | 431,228 | 913,187 | 825,231 | |||||
| Selling, general and administrative expenses | 47,157 | 42,470 | 98,371 | 86,612 | |||||
| Restructuring costs | 3,702 | 3 | 3,702 | 219 | |||||
| Operating income | 23,017 | 36,099 | 66,930 | 77,170 | |||||
| Interest expense and other finance costs | 21,306 | 16,855 | 42,257 | 33,135 | |||||
| Other expense (income) | (19,941 | ) | 3,945 | (20,284 | ) | 12,418 | |||
| Income before income taxes | 21,652 | 15,299 | 44,957 | 31,617 | |||||
| Current tax expense | 1,078 | 612 | 1,808 | 1,381 | |||||
| Deferred tax expense (recovery) | (5,612 | ) | 3,008 | 83 | 8,479 | ||||
| Income tax expense (recovery) | (4,534 | ) | 3,620 | 1,891 | 9,860 | ||||
| Net income including non-controlling interest | 26,186 | 11,679 | 43,066 | 21,757 | |||||
| Net income attributable to non-controlling interest | 4,039 | 1,087 | 5,524 | 2,209 | |||||
| Net income attributable to Kruger Products | 22,147 | 10,592 | 37,542 | 19,548 |
| Kruger Products Inc. | |||||||||||
| Unaudited Condensed Consolidated Statements of Cash Flows | |||||||||||
| (thousands of Canadian dollars) | |||||||||||
| 3-month period ended June 30, 2025 | 3-month period ended June 30, 2024 | 6-month period ended June 30, 2025 | 6-month period ended June 30, 2024 | ||||||||
| $ | $ | $ | $ | ||||||||
| Cash flows from (used in) operating activities | |||||||||||
| Net income including non-controlling interest | 26,186 | 11,679 | 43,066 | 21,757 | |||||||
| Items not affecting cash | |||||||||||
| Depreciation | 43,727 | 27,675 | 73,616 | 52,127 | |||||||
| Amortization | 2,008 | 1,496 | 3,980 | 2,561 | |||||||
| Loss (gain) on sale of property, plant and equipment | - | (2 | ) | (5 | ) | 269 | |||||
| Loss on disposal of leased assets | 23 | (632 | ) | 23 | - | ||||||
| Foreign exchange loss (gain) | (19,941 | ) | 3,945 | (20,284 | ) | 13,299 | |||||
| Interest expense and other finance costs | 21,306 | 16,855 | 42,257 | 33,135 | |||||||
| Pension and post-retirement benefits | 2,828 | 2,708 | 5,573 | 5,284 | |||||||
| Provisions | 1,065 | 1,045 | 3,929 | 2,118 | |||||||
| Income tax expense | (4,534 | ) | 3,620 | 1,891 | 9,860 | ||||||
| Loss on sale of non-financial assets | - | - | - | 12 | |||||||
| Total items not affecting cash | 46,482 | 56,710 | 110,980 | 118,665 | |||||||
| Net change in non-cash working capital | (29,511 | ) | 40,383 | (54,568 | ) | (45,687 | ) | ||||
| Contributions to pension and post-retirement benefit plans | (1,006 | ) | (1,111 | ) | (2,015 | ) | (2,264 | ) | |||
| Provisions paid | (4,024 | ) | (3,225 | ) | (4,024 | ) | (3,695 | ) | |||
| Income tax payments, net | (2,465 | ) | (2,101 | ) | (1,811 | ) | (2,441 | ) | |||
| Net cash from (used in) operating activities | 35,662 | 102,335 | 91,628 | 86,335 | |||||||
| Cash flows from (used in) investing activities | |||||||||||
| Purchases of property, plant and equipment | (7,717 | ) | (3,923 | ) | (9,862 | ) | (7,964 | ) | |||
| Purchases of property, plant and equipment related to the | |||||||||||
| Sherbrooke Expansion Project | (1,991 | ) | (43,554 | ) | (17,377 | ) | (89,427 | ) | |||
| Interest paid on credit facilities related to the Sherbrooke | |||||||||||
| Expansion Project | - | (2,673 | ) | - | (2,789 | ) | |||||
| Government assistance received | - | - | 3,150 | - | |||||||
| Purchases of software | (1,134 | ) | (240 | ) | (1,094 | ) | (287 | ) | |||
| Proceeds on sale of property, plant and equipment | - | 32 | - | 28 | |||||||
| Net cash used in investing activities | (10,842 | ) | (48,778 | ) | (25,183 | ) | (100,439 | ) | |||
| Cash flows from (used in) financing activities | |||||||||||
| Proceeds from long-term debt | 9,000 | 38,568 | 31,188 | 113,432 | |||||||
| Repayment of long-term debt | (22,507 | ) | (14,046 | ) | (32,505 | ) | (21,193 | ) | |||
| Payment of deferred financing fees | 39 | (365 | ) | 7 | (1,229 | ) | |||||
| Payment of lease liabilities | (7,714 | ) | (8,622 | ) | (16,737 | ) | (17,272 | ) | |||
| Change in restricted cash | (25,961 | ) | (29,786 | ) | (27,950 | ) | (31,198 | ) | |||
| Interest paid on long-term debt | (18,995 | ) | (14,516 | ) | (31,421 | ) | (23,379 | ) | |||
| Payment to related party | (5,800 | ) | (5,800 | ) | (5,800 | ) | (5,800 | ) | |||
| Dividends paid, net | (8,069 | ) | (7,804 | ) | (16,069 | ) | (9,557 | ) | |||
| Net cash from (used in) financing activities | (80,007 | ) | (42,371 | ) | (99,287 | ) | 3,804 | ||||
| Effect of exchange rate changes on cash and cash | |||||||||||
| equivalents held in foreign currency | (1,284 | ) | 428 | (1,311 | ) | 1,726 | |||||
| Increase (decrease) in cash and cash equivalents | |||||||||||
| during the period | (56,471 | ) | 11,614 | (34,153 | ) | (8,574 | ) | ||||
| Cash and cash equivalents - Beginning of period | 141,778 | 117,120 | 119,460 | 135,728 | |||||||
| Cash and cash equivalents - End of period | 85,307 | 127,154 | 85,307 | 127,154 |
| Kruger Products Inc. | |||||||||||
| Unaudited Segment and Geographic Results | |||||||||||
| (thousands of Canadian dollars) | |||||||||||
| 3-month period ended June 30, 2025 | 3-month period ended June 30, 2024 | 6-month period ended June 30, 2025 | 6-month period ended June 30, 2024 | ||||||||
| $ | $ | $ | $ | ||||||||
| Segment Information | |||||||||||
| Segment Revenue | |||||||||||
| Consumer | 449,222 | 421,925 | 914,412 | 826,214 | |||||||
| AFH | 86,858 | 87,875 | 167,778 | 163,018 | |||||||
| Revenue from external customers | 536,080 | 509,800 | 1,082,190 | 989,232 | |||||||
| Other segment items | |||||||||||
| Consumer | 380,038 | 361,628 | 769,176 | 703,255 | |||||||
| AFH | 77,895 | 78,306 | 156,026 | 145,679 | |||||||
| Corporate and other costs | 5,669 | 4,595 | 8,743 | 7,940 | |||||||
| Total other segment items | 463,602 | 444,529 | 933,945 | 856,874 | |||||||
| Adjusted EBITDA | |||||||||||
| Consumer | 69,184 | 60,297 | 145,236 | 122,959 | |||||||
| AFH | 8,963 | 9,569 | 11,752 | 17,339 | |||||||
| Corporate and other costs | (5,669 | ) | (4,595 | ) | (8,743 | ) | (7,940 | ) | |||
| Total Adjusted EBITDA | 72,478 | 65,271 | 148,245 | 132,358 | |||||||
| Reconciliation to net income: | |||||||||||
| Depreciation and amortization | 45,736 | 29,171 | 77,596 | 54,688 | |||||||
| Interest expense and other finance costs | 21,306 | 16,855 | 42,257 | 33,135 | |||||||
| Loss (gain) on sale of property, plant and equipment | 23 | (2 | ) | 18 | 269 | ||||||
| Loss on sale of non-financial assets | - | - | - | 12 | |||||||
| Change in amortized cost of Partnership unit liability | - | - | - | (881 | ) | ||||||
| Restructuring costs, net | 3,702 | 3 | 3,702 | 219 | |||||||
| Foreign exchange loss (gain) | (19,941 | ) | 3,945 | (20,284 | ) | 13,299 | |||||
| Income before income taxes | 21,652 | 15,299 | 44,956 | 31,617 | |||||||
| Income tax expense | (4,534 | ) | 3,620 | 1,891 | 9,860 | ||||||
| Net income including non-controlling interest | 26,186 | 11,679 | 43,065 | 21,757 | |||||||
| Geographic Revenue | |||||||||||
| Canada | 299,654 | 278,969 | 586,177 | 545,141 | |||||||
| US | 236,426 | 230,831 | 496,013 | 444,091 | |||||||
| Total revenue | 536,080 | 509,800 | 1,082,190 | 989,232 |
| KP Tissue Inc. | |||||
| Unaudited Condensed Statements of Financial Position | |||||
| (thousands of Canadian dollars) | |||||
| June 30, 2025 | December 31, 2024 | ||||
| $ | $ | ||||
| Assets | |||||
| Current assets | |||||
| Dividends receivable | 1,800 | 1,798 | |||
| 1,800 | 1,798 | ||||
| Non-current assets | |||||
| Investment in associate | 68,718 | 69,517 | |||
| Total assets | 70,518 | 71,315 | |||
| Liabilities | |||||
| Current liabilities | |||||
| Dividend payable | 1,800 | 1,798 | |||
| Total liabilities | 1,800 | 1,798 | |||
| Equity | |||||
| Common shares | 22,870 | 22,762 | |||
| Contributed surplus | 144,819 | 144,819 | |||
| Deficit | (115,830 | ) | (116,673 | ) | |
| Accumulated other comprehensive income | 16,859 | 18,609 | |||
| Total equity | 68,718 | 69,517 | |||
| Total liabilities and equity | 70,518 | 71,315 |
| KP Tissue Inc. | |||||||||||
| Unaudited Condensed Statements of Income | |||||||||||
| (thousands of Canadian dollars, except share and per share amounts) | |||||||||||
| 3-month period ended June 30, 2025 | 3-month period ended June 30, 2024 | 6-month period ended June 30, 2025 | 6-month period ended June 30, 2024 | ||||||||
| $ | $ | $ | $ | ||||||||
| Share of income | 2,755 | 1,344 | 4,672 | 2,499 | |||||||
| Depreciation of fair value increments | (279 | ) | (283 | ) | (563 | ) | (569 | ) | |||
| Equity income | 2,476 | 1,061 | 4,109 | 1,930 | |||||||
| Dilution gain | 95 | 131 | 209 | 393 | |||||||
| Net income | 2,571 | 1,192 | 4,318 | 2,323 | |||||||
| Basic earnings per share | 0.26 | 0.12 | 0.43 | 0.23 | |||||||
| Weighted average number of shares outstanding | 9,999,883 | 9,973,312 | 9,996,544 | 9,970,470 |
| KP Tissue Inc. | |||||||||||
| Unaudited Condensed Statements of Cash Flows | |||||||||||
| (thousands of Canadian dollars) | |||||||||||
| 3-month period ended June 30, 2025 | 3-month period ended June 30, 2024 | 6-month period ended June 30, 2025 | 6-month period ended June 30, 2024 | ||||||||
| $ | $ | $ | $ | ||||||||
| Cash flows from (used in) operating activities | |||||||||||
| Net income | 2,571 | 1,192 | 4,318 | 2,323 | |||||||
| Items not affecting cash | |||||||||||
| Equity income | (2,476 | ) | (1,061 | ) | (4,109 | ) | (1,930 | ) | |||
| Dilution gain | (95 | ) | (131 | ) | (209 | ) | (393 | ) | |||
| Total items not affecting cash | (2,571 | ) | (1,192 | ) | (4,318 | ) | (2,323 | ) | |||
| Decrease in payable to investee | - | (200 | ) | - | (284 | ) | |||||
| Tax refunds, net | - | 200 | - | 284 | |||||||
| Net cash from (used in) operating activities | - | - | - | - | |||||||
| Cash flows from investing activities | |||||||||||
| Dividends received, net | 1,746 | 1,744 | 3,490 | 3,496 | |||||||
| Net cash from investing activities | 1,746 | 1,744 | 3,490 | 3,496 | |||||||
| Cash flows used in financing activities | |||||||||||
| Dividends paid, net | (1,746 | ) | (1,744 | ) | (3,490 | ) | (3,496 | ) | |||
| Net cash used in financing activities | (1,746 | ) | (1,744 | ) | (3,490 | ) | (3,496 | ) | |||
| Increase (decrease) in cash and cash equivalents | |||||||||||
| during the period | - | - | - | - | |||||||
| Cash and cash equivalents - Beginning of period | - | - | - | - | |||||||
| Cash and cash equivalents - End of period | - | - | - | - |

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment